H-CYTE, Inc. (HCYT)

3.6000 0.0000 (0.00%) At close: 09:53AM EDT

H-CYTE, Inc.

2202 North West Shore Boulevard
Suite 200
Tampa, FL 33607
United States
888 664 2983
https://www.hcyte.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael W. Yurkowsky	CEO & Director	180k	N/A	1972
Mr. Jeremy D. Daniel	Chief Financial Officer	200k	N/A	1976
Dr. Tanya Rhodes Ph.D.	Chief Scientific Officer	252k	N/A	1961
Mr. Jeffery Wright CPA, CPA	Controller & Principal Accounting Officer	N/A	N/A	1983

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

Corporate Governance

H-CYTE, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.